Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives $15.55 Consensus Price Target from Brokerages

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) have been assigned a consensus recommendation of “Hold” from the fourteen brokerages that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, nine have assigned a hold recommendation and four have given a buy recommendation to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $15.55.

Several equities research analysts have recently commented on FOLD shares. The Goldman Sachs Group lifted their target price on Amicus Therapeutics from $9.00 to $11.00 and gave the company a “neutral” rating in a research note on Wednesday, November 5th. Wall Street Zen upgraded Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Guggenheim cut Amicus Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, January 5th. Needham & Company LLC lowered shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, December 19th. Finally, TD Cowen downgraded shares of Amicus Therapeutics from a “buy” rating to a “hold” rating and set a $14.50 price target for the company. in a research note on Monday, December 22nd.

Amicus Therapeutics Price Performance

Shares of FOLD stock opened at $14.27 on Friday. Amicus Therapeutics has a 1 year low of $5.51 and a 1 year high of $14.38. The company has a current ratio of 2.99, a quick ratio of 2.09 and a debt-to-equity ratio of 1.70. The firm’s 50 day moving average is $12.61 and its 200-day moving average is $9.49. The firm has a market capitalization of $4.48 billion, a price-to-earnings ratio of -356.66 and a beta of 0.42.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.17 earnings per share for the quarter, beating analysts’ consensus estimates of $0.12 by $0.05. Amicus Therapeutics had a negative net margin of 2.35% and a positive return on equity of 6.95%. The business had revenue of $169.06 million during the quarter, compared to analyst estimates of $165.24 million. During the same quarter last year, the business posted $0.10 earnings per share. Amicus Therapeutics’s revenue for the quarter was up 19.5% compared to the same quarter last year. Sell-side analysts forecast that Amicus Therapeutics will post 0.15 EPS for the current fiscal year.

Insider Buying and Selling at Amicus Therapeutics

In related news, insider David Michael Clark sold 25,642 shares of Amicus Therapeutics stock in a transaction on Friday, December 19th. The stock was sold at an average price of $14.17, for a total transaction of $363,347.14. Following the completion of the sale, the insider directly owned 245,690 shares of the company’s stock, valued at $3,481,427.30. The trade was a 9.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Ellen Rosenberg sold 23,621 shares of the company’s stock in a transaction dated Wednesday, November 26th. The shares were sold at an average price of $10.00, for a total value of $236,210.00. Following the completion of the sale, the insider owned 507,710 shares of the company’s stock, valued at $5,077,100. This represents a 4.45% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 420,450 shares of company stock worth $4,730,250 over the last quarter. 2.20% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Amicus Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Signaturefd LLC increased its holdings in shares of Amicus Therapeutics by 32.7% during the fourth quarter. Signaturefd LLC now owns 2,895 shares of the biopharmaceutical company’s stock worth $41,000 after purchasing an additional 714 shares during the period. GAMMA Investing LLC grew its position in Amicus Therapeutics by 167.1% during the fourth quarter. GAMMA Investing LLC now owns 1,987 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 1,243 shares in the last quarter. Allworth Financial LP increased its stake in Amicus Therapeutics by 36.3% during the 3rd quarter. Allworth Financial LP now owns 4,678 shares of the biopharmaceutical company’s stock worth $37,000 after acquiring an additional 1,246 shares during the period. Allianz Asset Management GmbH increased its stake in Amicus Therapeutics by 0.3% during the 3rd quarter. Allianz Asset Management GmbH now owns 389,109 shares of the biopharmaceutical company’s stock worth $3,066,000 after acquiring an additional 1,333 shares during the period. Finally, Van ECK Associates Corp raised its holdings in Amicus Therapeutics by 35.1% in the 3rd quarter. Van ECK Associates Corp now owns 5,638 shares of the biopharmaceutical company’s stock valued at $44,000 after acquiring an additional 1,466 shares in the last quarter.

About Amicus Therapeutics

Amicus Therapeutics (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company’s lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.